Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Celldex Therapeutics Inc (GB:0HUU)
LSE:0HUU
Holding GB:0HUU?
Track your performance easily
0HUU Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.44 - $0.44
Previous Close$0.44
Volume0.00
Average Volume (3M)N/A
Market Cap
$1.91B
Enterprise Value$1.11B
Total Cash (Recent Filing)$802.32M
Total Debt (Recent Filing)$2.38M
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Nov 06, 2024EPS Estimate
-$0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.74
Shares Outstanding66,287,596
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)0.03
Price to Sales (P/S)229.48
Price to Cash Flow (P/CF)-16.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue133.12
Enterprise Value/Gross Profit160.57
Enterprise Value/Ebitda-10.43
Forecast
1Y Price Target
$63.00Price Target Upside14218.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Celldex News
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessStrong statistical significance in Ph. 2 results and CLDX replicating Ph. 2’s design in Ph. 3 while adding loading doses give confidence that barzo can succeed in Ph. 3 and demonstrate best-in-class efficacy.
Efficacy And SafetyCLDX's lead asset barzolvolimab remains the clear leader in this space, having demonstrated substantially more robust efficacy with a well-tolerated safety profile.
Long-term DurabilityThe new 52-week data demonstrate barzo has long-term durability, is effective regardless of omalizumab experience, and critically, maintains a manageable safety and tolerability profile.
Bears Say
Efficacy ConcernsThe topline Phase 2 CIndU efficacy appears lower than the prior Phase 1 data.
Market CompetitionPotential approvals for Xolair biosimilars, Dupixent, and remibrutinib will likely confine barzo exclusively to 2L+, which is believed to be a smaller opportunity than CLDX projected.
Safety IssuesConcerns around a potential anaphylaxis AE for barzo is weighing on shares.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.36% Insiders
37.26% Mutual Funds
0.55% Other Institutional Investors
49.87% Public Companies and
Individual Investors
0HUU FAQ
What was Celldex Therapeutics Inc’s price range in the past 12 months?
Celldex Therapeutics Inc lowest share price was $0.44 and its highest was $0.44 in the past 12 months.
What is Celldex Therapeutics Inc’s market cap?
Currently, no data Available
When is Celldex Therapeutics Inc’s upcoming earnings report date?
Celldex Therapeutics Inc’s upcoming earnings report date is Nov 06, 2024 which is in 18 days.
How were Celldex Therapeutics Inc’s earnings last quarter?
Celldex Therapeutics Inc released its earnings results on Aug 08, 2024. The company reported -$0.54 earnings per share for the quarter, beating the consensus estimate of -$0.588 by $0.048.
Is Celldex Therapeutics Inc overvalued?
According to Wall Street analysts Celldex Therapeutics Inc’s price is currently Undervalued.
Does Celldex Therapeutics Inc pay dividends?
Celldex Therapeutics Inc does not currently pay dividends.
What is Celldex Therapeutics Inc’s EPS estimate?
Celldex Therapeutics Inc’s EPS estimate is -$0.67.
How many shares outstanding does Celldex Therapeutics Inc have?
Celldex Therapeutics Inc has 66,287,600 shares outstanding.
What happened to Celldex Therapeutics Inc’s price movement after its last earnings report?
Celldex Therapeutics Inc reported an EPS of -$0.54 in its last earnings report, beating expectations of -$0.588. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Celldex Therapeutics Inc?
Among the largest hedge funds holding Celldex Therapeutics Inc’s share is Woodline Partners LP. It holds Celldex Therapeutics Inc’s shares valued at 28M.
---
Celldex Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$63.00 (14218.18% Upside)
$63.00 (14218.18% Upside)
Blogger Sentiment
Bullish
GB:0HUU Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
17.70%
12-Months-Change
Fundamentals
Return on Equity
-27.53%
Trailing 12-Months
Asset Growth
182.51%
Trailing 12-Months
Company Description
Celldex Therapeutics Inc
Celldex Therapeutics, Inc. engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.
---
0HUU Stock 12 Month Forecast
Average Price Target
$63.00
▲(14218.18% Upside)
Technical Analysis
Best Analysts Covering 0HUU
1 Year
1 Year Success Rate
9/13 ratings generated profit
1 Year Average Return
+107.92%
reiterated a buy rating last month
Copying Kristen Kluska's trades and holding each position for 1 Year would result in 69.23% of your transactions generating a profit, with an average return of +107.92% per trade.
---